ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Educational Symposium

Strategies to Control Chronic Hyperkalemia in Patients with CKD and ESRD

October 22, 2020 | 01:00 PM - 02:00 PM

Location: Simulive

Session Description

Hyperkalemia is a common complication in patients with advanced CKD and ESRD and is associated with higher mortality, cardiovascular complications, and healthcare utilization. Due to its potential to cause malignant arrhythmias, severe hyperkalemia typically commands emergency therapy to correct plasma potassium concentration, followed by interventions aimed at preventing its reoccurrence. Many interventions create a therapeutic dilemma, as they result in patients' deprivation of the potentially beneficial effects of medications such as renin-angiotensin-aldosterone system inhibitors (RAASi) or the benefits of heart-healthy diets.

The recent development of novel potassium binders has resulted in the expansion of our abilities to prevent recurrent hyperkalemia in at-risk patient populations without compromising on the administration of otherwise beneficial interventions such as RAASi or heart-healthy diets. Clinical trials have proven that the chronic administration of potassium binders results in persistent normokalemia, and it enables the utilization of RAASi in hyperkalemia-prone individuals. The clinical benefits of these strategies are yet to be determined and are the focus of ongoing investigations.

Support is provided by an educational grant from Relypsa, Inc., A Vifor Pharma Group Company.

Learning Objective(s)

  • Describe the risk factors of chronic hyperkalemia and the impact of hyperkalemia on clinical outcomes
  • Discuss the mechanisms of action, clinical efficacy, and safety of novel potassium binders for use in clinical practice

Learning Pathway(s)

  • Chronic Kidney Disease

Moderator

  • Elvira O. Gosmanova, MD, FASN

Presentations

  • Introduction
    01:00 PM - 01:10 PM
    Elvira O. Gosmanova, MD, FASN
  • Hyperkalemia in CKD and ESRD: Characteristics and Clinical Relevance
    01:10 PM - 01:35 PM
    David S. Goldfarb, MD, FASN
  • Treatment of Chronic Hyperkalemia: Fixing a Biochemical Parameter or Improving Clinical Outcomes?

    01:35 PM - 02:00 PM
    James M. Luther, MD, FASN